Hepatoprotective and neuroprotective effect of taxifolin on hepatic encephalopathy in rats

ArticleAçık Erişim

Özet

This study was planned to assess the potential protective effects of taxifolin against thioacetamide-induced hepatic encephalopathy and subsequently to portray its behavioural results. The experimental model was induced with three doses of (200 mg/kg i.p.) thioacetamide and taxifolin (50 and 100 mg/kg, p.o.) was administered for fourteen days. Taxifolin effectively attenuated hepatic encephalopathy through decrease in AST, ALT, ALP and LDH concentrations and improvement of hyperammonemia, and increase in antioxidant capacity by decreasing MDA, ROS, and increasing CAT and GSH. In addition, the expressions of NF-κB, TNF-α, IL-1β, caspase-3 and Bax was down-regulated while IL-10 and Bcl-2 expressions were up-regulated with taxifolin treatment. The recovery was confirmed by downregulation of iNOS and 8-OHdG expressions in our immunohistochemical analysis. Taxifolin treatment reduced the disrupting role of thioacetamide as seen by corrected hyperammonemia as well as preservation of astrocyte and hepatocyte structure. Elevated plus maze and locomotor activity tests also proved that taxifolin might repeal the neurobehavioral disabilities. In conclusion, taxifolin has shown hepatoprotective and neuroprotective roles with antioxidant and anti-inflammatory effects, as well as suppressing the excessive release of ammonia, and it eventually reversed neurobehavioral impairments. Graphical abstract: [Figure not available: see fulltext.]. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/12980Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s11011-022-00952-3Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorOkkay, Ufuk
dc.contributor.authorFerah Okkay, Irmak
dc.contributor.authorCicek, Betul
dc.contributor.authorAydin, Ismail Cagri
dc.contributor.authorOzkaraca, Mustafa
dc.date.accessioned2026-10-18T20:27:50.096987458Z
dc.date.available2026-10-18T20:27:50.096987458Z
dc.date.issued2022
dc.description.abstractThis study was planned to assess the potential protective effects of taxifolin against thioacetamide-induced hepatic encephalopathy and subsequently to portray its behavioural results. The experimental model was induced with three doses of (200 mg/kg i.p.) thioacetamide and taxifolin (50 and 100 mg/kg, p.o.) was administered for fourteen days. Taxifolin effectively attenuated hepatic encephalopathy through decrease in AST, ALT, ALP and LDH concentrations and improvement of hyperammonemia, and increase in antioxidant capacity by decreasing MDA, ROS, and increasing CAT and GSH. In addition, the expressions of NF-κB, TNF-α, IL-1β, caspase-3 and Bax was down-regulated while IL-10 and Bcl-2 expressions were up-regulated with taxifolin treatment. The recovery was confirmed by downregulation of iNOS and 8-OHdG expressions in our immunohistochemical analysis. Taxifolin treatment reduced the disrupting role of thioacetamide as seen by corrected hyperammonemia as well as preservation of astrocyte and hepatocyte structure. Elevated plus maze and locomotor activity tests also proved that taxifolin might repeal the neurobehavioral disabilities. In conclusion, taxifolin has shown hepatoprotective and neuroprotective roles with antioxidant and anti-inflammatory effects, as well as suppressing the excessive release of ammonia, and it eventually reversed neurobehavioral impairments. Graphical abstract: [Figure not available: see fulltext.]. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
dc.description.sponsorshipThis work was supported by Research Fund of the Ataturk University. (Project Number: TSA-2019–7527).
dc.identifier.doi10.1007/s11011-022-00952-3
dc.identifier.eissn1573-7365
dc.identifier.endpage1556
dc.identifier.issn0885-7490
dc.identifier.issue5
dc.identifier.pmid35298730
dc.identifier.scopus2-s2.0-85126471187
dc.identifier.startpage1541
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/12980
dc.identifier.volume37
dc.identifier.wosWOS:000770222800001
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofMetabolic Brain Disease
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectApoptosis
dc.subjectHepatic encephalopathy
dc.subjectInflammation
dc.subjectOxidative stress
dc.subjectTaxifolin
dc.subjectThioacetamide
dc.subjectAnimals
dc.subjectAntioxidants
dc.subjectHyperammonemia
dc.subjectLiver
dc.subjectNeuroprotective Agents
dc.subjectQuercetin
dc.subjectRats
dc.subjectRats, Wistar
dc.subject8 hydroxydeoxyguanosine
dc.subjectalanine aminotransferase
dc.subjectalkaline phosphatase
dc.subjectammonia
dc.subjectaspartate aminotransferase
dc.subjectcaspase 3
dc.subjectcatalase
dc.subjectglutathione
dc.subjectimmunoglobulin enhancer binding protein
dc.subjectinducible nitric oxide synthase
dc.subjectinterleukin 10
dc.subjectinterleukin 1beta
dc.subjectlactate dehydrogenase
dc.subjectmalonaldehyde
dc.subjectprotein Bax
dc.subjectprotein bcl 2
dc.titleHepatoprotective and neuroprotective effect of taxifolin on hepatic encephalopathy in rats
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus35
rdl.citation.wos32
rdl.departmentPhysiology Department, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey. | Pharmacology Department, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)